Literature DB >> 25223825

Author's reply to Wendling and Prati: "treat-to-target in spondyloarthritis: implications for clinical trial designs".

James Cheng-Chung Wei1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25223825     DOI： 10.1007/s40265-014-0289-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  12 in total

1.  Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?

Authors:  Lihi Eder; Vinod Chandran; Hua Shen; Richard J Cook; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2010-07-13       Impact factor: 19.103

2.  Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Authors:  Daniel Wendling; Clément Prati
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

3.  Spondyloarthritis: a window of opportunity?

Authors:  Pascal Claudepierre
Journal:  Joint Bone Spine       Date:  2014-05-01       Impact factor: 4.929

4.  Adalimumab: in non-radiographic axial spondyloarthritis.

Authors:  Celeste B Burness; Emma D Deeks
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

Review 5.  Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

Authors:  Johanna Callhoff; Joachim Sieper; Anja Weiß; Angela Zink; Joachim Listing
Journal:  Ann Rheum Dis       Date:  2014-04-09       Impact factor: 19.103

6.  Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.

Authors:  Pedro Machado; Robert Landewé; Elisabeth Lie; Tore K Kvien; Jürgen Braun; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-11-10       Impact factor: 19.103

Review 7.  Treat-to-target in spondyloarthritis: implications for clinical trial designs.

Authors:  James Cheng-Chung Wei
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

8.  Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?

Authors:  Walter P Maksymowych
Journal:  Nat Rev Rheumatol       Date:  2013-08-06       Impact factor: 20.543

Review 9.  Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.

Authors:  M M Schoels; J Braun; M Dougados; P Emery; O Fitzgerald; A Kavanaugh; T K Kvien; R Landewé; T Luger; P Mease; I Olivieri; J Reveille; C Ritchlin; M Rudwaleit; J Sieper; J S Smolen; M de Wit; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

10.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.

Authors:  Josef S Smolen; Jürgen Braun; Maxime Dougados; Paul Emery; Oliver Fitzgerald; Philip Helliwell; Arthur Kavanaugh; Tore K Kvien; Robert Landewé; Thomas Luger; Philip Mease; Ignazio Olivieri; John Reveille; Christopher Ritchlin; Martin Rudwaleit; Monika Schoels; Joachim Sieper; Martinus de Wit; Xenofon Baraliakos; Neil Betteridge; Ruben Burgos-Vargas; Eduardo Collantes-Estevez; Atul Deodhar; Dirk Elewaut; Laure Gossec; Merryn Jongkees; Mara Maccarone; Kurt Redlich; Filip van den Bosch; James Cheng-Chung Wei; Kevin Winthrop; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-08       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.